Clinical Development

• Optimizing Regulatory Frameworks for Gene Therapies in Rare Diseases: Challenges and solutions

  December 12, 2024 Position Paper Regulatory Policy , Clinical Development , CMC
  Read Statement

• Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies

  September 26, 2024 FDA Regulatory Policy , Clinical Development , Bioethics , FDA Guidance
  Read Statement

• Platform Technology Designation Program for Drug Development

  August 27, 2024 FDA Regulatory Policy , Clinical Development , CMC , FDA Guidance
  Read Statement

• Request for Information from Stakeholders on the Enacted Cures 2.0 Act

  August 02, 2024 Congress Regulatory Policy , Clinical Development , Research Funding , New Technologies
  Read Statement

• Safety Testing of Human Allogeneic Cells Expanded for Use in Cell-Based Medical Products

  July 29, 2024 FDA Regulatory Policy , Clinical Development , FDA Guidance
  Read Statement

• Considerations for the Use of Human-and Animal-Derived Materials in the Manufacture of Cell and Gene Therapy and Tissue-Engineered Medical Products

  July 26, 2024 FDA Regulatory Policy , Clinical Development , CMC , FDA Guidance
  Read Statement

• Comments on Predecisional Draft NCATS Strategic Plan 2024- 2029 

  June 14, 2024 Miscellaneous Regulatory Policy , Clinical Development , CMC , Research Funding , New Technologies , NBS
  Read Statement

• Potency Assurance for Cellular and Gene Therapy Products

  March 26, 2024 FDA Regulatory Policy , Clinical Development , CMC , FDA Guidance
  Read Statement

• Written Testimony: Legislative Proposals to Support Patients with Rare Diseases

  March 19, 2024 Congress Clinical Development , Research Funding , New Technologies
  Read Statement

• Advanced Manufacturing Technologies Designation Program

  March 05, 2024 FDA Regulatory Policy , Clinical Development , CMC , FDA Guidance
  Read Statement

• RFI: Improving Americans’ Access to Gene Therapies

  January 22, 2024 Congress Regulatory Policy , Clinical Development , Payment Policy
  Read Statement

• RFI: Scientific Challenges and Opportunities to Advance the Development of Individualized Cellular and Gene Therapies

  November 16, 2023 FDA Regulatory Policy , Clinical Development
  Read Statement

• Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products

  November 13, 2023 FDA Regulatory Policy , Clinical Development , CMC , FDA Guidance
  Read Statement

• Advancing the Utilization and Supporting the Implementation of Innovative Manufacturing Approaches

  July 07, 2023 FDA Regulatory Policy , Clinical Development
  Read Statement

• Methods and Approaches for Capturing Post-Approval Safety and Efficacy Data on CGT Products Listening Session

  May 26, 2023 FDA Regulatory Policy , Clinical Development
  Read Statement

• Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products Guidance

  May 02, 2023 FDA Regulatory Policy , Clinical Development , FDA Guidance
  Read Statement

  1 2 3 4